New Antibody Treatment Showing Promising Results

Communicated Content

Communicated Content

A relatively new antibody treatment to treat COVID-19 before hospitalization is showing promising results, and can be made available easily.

A relatively new antibody treatment to treat COVID-19 before hospitalization is showing promising results, and can be made available easily.

The COVID Plasma Initiative, which arranged the highly successful plasma drives in Crown Heights, released a document addressing the new treatment and listing the hospitals that offer up-to-date treatments.

Below is the full text of their release:

If you have high risk factors (ie. over 65, obesity , diabetes, hypertension etc.) and were exposed to COVID-19, or have symptoms, take a test.

If you tested positive and you are at risk, contact your doctor immediately to discuss whether monoclonal antibody treatment, (Regeneron® or Eli Lilly®) is appropriate for you, and if so, to arrange access.

COVID-19 can cause “ silent hypoxia” even to low-risk patients, meaning the patient doesn’t realize that their oxygen level is dropping. A pulse oximeter is simple to use and can identify this early. It is better to arrive at the hospital earlier than later, certainly if oxygen levels begin to drop. Consult medical advice if levels drop below 95.

If you need to be hospitalized do not “wait and see”!

Choose a hospital with up-to-date treatments: plasma, steroids, blood
thinners etc.

CPI currently recommends Mt. Sinai (NYC)

Hospitals currently providing monoclonal antibodies (partialiist):
Mt. Sinai (NYC)
Maimonides (Brooklyn)
Northwell (SI and LI)
Good Samaritan (Rockland)
Monmouth Medical Center South Campus (Lakewood, NJ)
Hackensack Meridian Health (NJ)

Please note that not all hospitals on this list are similarly recommended for COVID-19 inpatient care.

Disclaimer: the above are general suggestions, not to be construed as medical advice, and should be discussed with your healthcare provider.

Discussion
In keeping in line with the Rabbonim's policies for websites, we do not allow comments. However, our Rabbonim have approved of including input on articles of substance (Torah, history, memories etc.)

We appreciate your feedback. If you have any additional information to contribute to this article, it will be added below.

Leave a Comment

Your email address will not be published. Required fields are marked *

advertise package